29 related articles for article (PubMed ID: 1428262)
1. Educational paper: decreasing the burden of cardiovascular disease in childhood cancer survivors: an update for the pediatrician.
Dillenburg RF; Nathan P; Mertens L
Eur J Pediatr; 2013 Sep; 172(9):1149-60. PubMed ID: 23361962
[TBL] [Abstract][Full Text] [Related]
2. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy.
Pinarli FG; Oğuz A; Tunaoğlu FS; Karadeniz C; Gökçora N; Elbeg S
Pediatr Blood Cancer; 2005 Apr; 44(4):370-7. PubMed ID: 15602715
[TBL] [Abstract][Full Text] [Related]
3. Signal-averaged electrocardiography in children with anthracycline-induced cardiomyopathy.
Vaksmann G; Gutierrez R; Duhamel A; Nelken B; Francart C; Kouakam C; Mazingue F; Rey C
Pediatr Cardiol; 2001; 22(6):494-8. PubMed ID: 11894153
[TBL] [Abstract][Full Text] [Related]
4. Automatic border detection identifies subclinical anthracycline cardiotoxicity in children with malignancy.
Hashimoto I; Ichida F; Miura M; Okabe T; Kanegane H; Uese K; Hamamichi Y; Misaki T; Koizumi S; Miyawaki T
Circulation; 1999 May; 99(18):2367-70. PubMed ID: 10318655
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of anthracycline-induced late cardiomyopathy by exercise-spiroergometry and stress-echocardiography.
Hauser M; Gibson BS; Wilson N
Eur J Pediatr; 2001 Oct; 160(10):607-10. PubMed ID: 11686505
[TBL] [Abstract][Full Text] [Related]
6. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
Elbl L; Hrstkova H; Tomaskova I; Michalek J
Support Care Cancer; 2006 Feb; 14(2):128-36. PubMed ID: 16034614
[TBL] [Abstract][Full Text] [Related]
7. Ventricular late potentials: another expression of cardiotoxicity of cytostatic drugs in children?
Tamminga RY; Bink-Boelkens MT; Kievit J
Int J Cardiol; 1992 Sep; 36(3):283-8. PubMed ID: 1428262
[TBL] [Abstract][Full Text] [Related]
8. [Anthracycline-induced cardiomyopathy].
Roul G; Cohen C; Lieber A
Presse Med; 2009 Jun; 38(6):987-94. PubMed ID: 19423276
[TBL] [Abstract][Full Text] [Related]
9. [Pathogenesis, prevention and detection of cardiotoxicity of anthracycline cytostatic agents].
Mladosievicová B; Hulín I; Krcméry V; Petrásová H; Kollárová H
Bratisl Lek Listy; 1994 Jul; 95(7):304-22. PubMed ID: 7812833
[TBL] [Abstract][Full Text] [Related]
10.
Laursen AH; Thune JJ; Hutchings M; Hasbak P; Kjaer A; Elming MB; Ripa RS
Clin Physiol Funct Imaging; 2018 Mar; 38(2):176-185. PubMed ID: 28251781
[TBL] [Abstract][Full Text] [Related]
11. [Late ventricular potentials: significance, electrophysiology and clinical importance in coronary disease].
Zimmermann M
Praxis (Bern 1994); 1996 Apr; 85(18):604-12. PubMed ID: 8701165
[TBL] [Abstract][Full Text] [Related]
12. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.
Kremer LC; van der Pal HJ; Offringa M; van Dalen EC; Voûte PA
Ann Oncol; 2002 Jun; 13(6):819-29. PubMed ID: 12123328
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
